Background {#Sec1}
==========

Progressive multifocal leukoencephalopathy (PML) is a rare but frequently fatal demyelinating disease caused by JC virus (JCV) \[[@CR1]--[@CR3]\]. In PML, pathogenic variants of JCV invade the brain either within B cells or as cell-free virus, and infect oligodendrocytes, leading to the apoptosis of infected oligodendrocytes and multifocal demyelination, particularly under conditions of reduced immune surveillance in the central nervous system \[[@CR1]--[@CR4]\]. Some disease-modifying drugs (DMDs) for multiple sclerosis (MS) can cause PML \[[@CR5]\]. Following the long-term usage of natalizumab, MS patients with anti-JCV antibody, particularly those with a high antibody index, have a high risk of developing PML \[[@CR6]--[@CR8]\]. Although the incidence rate of fingolimod-associated PML was estimated to be low (0.056--0.069 per 1000 individuals) worldwide, especially in Europe and the USA \[[@CR5], [@CR9]\], 4 Japanese patients on fingolimod have developed PML to date, and the incidence rate of fingolimod-associated PML in Japan is estimated to be 10 times higher (0.58--0.65 per 1000) than other countries \[[@CR10]--[@CR12]\]. However, the reason for this remains to be elucidated.

A previous study reported that Scandinavian and German MS patients with anti-JCV antibodies had a significantly lower frequency of the *human leukocyte antigen* (*HLA*)*-DRB1\*15* haplotype than those without anti-JCV antibodies, suggesting the *DRB1\*15* haplotype is negatively associated with anti-JCV antibody positivity \[[@CR13]\]. A recent Spanish study revealed that older age increased anti-JCV antibody positivity while *HLA-DRB1\*15:01* carriers had marginally lower anti-JCV antibody positivity rates than *DRB1\*15:01* non-carriers (*p* = 0.056) \[[@CR14]\]. These findings suggest that anti-JCV antibody serostatus are influenced by *HLA* class II alleles.

Although the detailed mechanism of JCV clearance by a host remains to be elucidated, the immune control of JCV mostly depends on cellular immunity \[[@CR2]--[@CR4]\]. Although high titres of anti-JCV antibodies do not prevent the development of PML \[[@CR4], [@CR15]--[@CR18]\], they can be used as a predictive marker for natalizumab-PML in MS patients \[[@CR6]--[@CR8]\]. It is postulated that host CD4^+^ T cells recognizing JCV antigens secrete proinflammatory cytokines that upregulate HLA class I molecules on JCV-infected cells, and that the presentation of viral antigens by HLA class I molecules promotes CD8^+^ cytotoxic T cells to eliminate JCV-infected cells \[[@CR19]\]. This CD4^+^ T cell response varies according to *HLA* class II alleles \[[@CR20]\], resulting in distinct forms of JCV clearance. Because high levels of anti-JCV antibodies might reflect the high replicative activity of JCV under poor viral clearance whereas negative or low JCV antibody levels reflect strong viral clearance \[[@CR13], [@CR21]--[@CR24]\], differences in CD4^+^ T cell responses by *HLA* class II alleles might be related to anti-JCV antibody serostatus.

The genetic backgrounds of MS differ between Caucasians and Japanese. Although *HLA*-*DRB1\*15:01* is strongly associated with MS in Europeans and Japanese, *DRB1\*04:05*, which is rare in Caucasians, is also a frequent and strong genetic risk factor in Japanese \[[@CR25]--[@CR29]\]. Therefore, we hypothesized that distinct disease-susceptible *HLA* class II alleles between Caucasian and Japanese patients with MS are associated with differences in JCV clearance and anti-JCV antibody serostatus, which may in part be related to the difference in risk for fingolimod-PML between Caucasian and Japanese patients. Because DNA from Japanese patients with fingolimod-PML was not available for *HLA* genotyping, we studied the relationship between anti-JCV antibody serostatus and *HLA* class II alleles in Japanese MS patients with and without fingolimod to assess whether MS-susceptible *HLA* class II alleles influenced anti-JCV antibody serostatus. The results of the current study suggest why fingolimod-PML risk is higher in Japanese patients compared with Caucasian patients.

Methods {#Sec2}
=======

Participants {#Sec3}
------------

We enrolled 128 Japanese patients with MS in this study. Patients were recruited from the Department of Neurology at Kyushu University Hospital (Fukuoka, Japan), Kyoto Min-Iren-Chuo Hospital (Kyoto, Japan) and Kaikoukai Jyousai Hospital (Nagoya, Japan). A diagnosis of MS was based on the 2010 McDonald criteria \[[@CR30]\]. Medical records and laboratory data of patients were retrospectively reviewed. Disease severity was evaluated using Kurtzke's Expanded Disability Status Scale (EDSS) \[[@CR31]\]. Serum samples were collected between 1 July 2014 and 31 December 2018 and stored at − 80 °C at each hospital.

Standard protocol approval, registration, and patient consent {#Sec4}
-------------------------------------------------------------

This study was reviewed and approved by the Ethical Committee of Kyushu University (approved number 575--08). All patients provided written informed consent.

Measurement of anti-JCV antibody {#Sec5}
--------------------------------

Serum anti-JCV antibody serostatus and index were determined using a second-generation two-step assay \[[@CR32]\] performed at Focus Diagnostics (Cypress, CA, USA).

*HLA* class II genotyping {#Sec6}
-------------------------

Genotyping of the *HLA-DRB1* and *-DPB1* alleles of participants was performed by hybridization between polymerase chain reaction amplification products of the genes and sequence-specific oligonucleotide probes as described previously \[[@CR33]\].

Statistics {#Sec7}
----------

Categorical variables were described by counts and percentages, and continuous and ordinal variables by median and interquartile ranges (IQRs) (and range, if necessary). Demographic features were compared between anti-JCV antibody-positive and antibody-negative groups using Fisher's exact test or the Wilcoxon test. Anti-JCV antibody frequency and index were also compared between two groups using Fisher's exact test and the Wilcoxon test, respectively. In addition to the comparison of anti-JCV antibody frequency and index between patients with and without each *HLA* allele (shown as four-digits), we also compared them between *HLA* allele groups (shown as two-digits), which reflect HLA serotypes, on the basis of their similar function in each allele group. The associations between anti-JCV antibody index and age, months of treatment with fingolimod, and number of lymphocytes were tested using linear regression models. The linear dose effect of each *HLA* allele on anti-JCV antibody seropositivity was evaluated with the Cochran--Armitage trend test. A multivariable logistic regression model was used to identify independent factors that predicted the positivity of anti-JCV antibody. All analyses were performed using JMP® Pro version 14.1.0 software (SAS Institute, Cary, NC, USA). The significance level was set at *p* \<  0.05.

Results {#Sec8}
=======

Demographics and anti-JCV antibody status of participants {#Sec9}
---------------------------------------------------------

The demographics and anti-JCV antibody status of participants are shown in Table [1](#Tab1){ref-type="table"}. Of 128 patients with MS, 83 (64.8%) had a history of fingolimod usage and 64 (50.0%) were under treatment with fingolimod at sampling. Eighty-six participants (67.2%) were positive for anti-JCV antibody and the median anti-JCV antibody index was 1.19 (IQR = 0.21--3.09). Table 1Demographic features and anti-JCV antibody status of study participantsMS patients\
(*n* = 128)Sex, female93 (72.7%)Age, years39 \[IQR 32--48; range 20--70\]Disease duration, years10 \[IQR 5--16; range 0--43\]EDSS score2.0 \[IQR 1.0--3.5; range 0--8.0\]Lymphocyte counts at sampling, /μL709 \[IQR 447--1539; range 222--3491\]History of fingolimod usage83 (64.8%)Use of fingolimod at sampling^a^64 (50.0%)Anti-JCV antibody, positive86 (67.2%)Anti-JCV antibody index1.19 \[IQR 0.21--3.09; range 0.06--4.04\]Values indicate the median \[IQR and range\] or count (%)*EDSS* Expanded Disability Status Scale, *IQR* interquartile range, *JCV* JC virus, *MS* multiple sclerosis^a^Other disease-modifying drugs were used in 39 patients (30.5%) at sampling: interferon-β-1a in 15 (11.7%), dimethyl fumarate in 13 (10.2%), glatiramer acetate in 4 (3.1%), natalizumab in 3 (2.3%), interferon-β-1b in 2 (1.6%), azathioprine in 1 (0.8%), and methotrexate in 1 (0.8%)

*HLA* class II alleles in participants {#Sec10}
--------------------------------------

Phenotype frequencies of the *HLA* class II of participants are shown in Additional file [1](#MOESM1){ref-type="media"}: Table S1. By four-digit alleles, 51 participants (39.8%) carried *HLA-DRB1\*04:05* and 42 (32.8%) had *DRB1\*15:01*. By two-digit alleles, 81 (63.3%) had *HLA-DRB1\*04* and 65 (50.8%) had *DRB1\*15*. The phenotype frequencies were not significantly different between MS patients with and without fingolimod treatment (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Age is positively associated with anti-JCV antibody positivity and index {#Sec11}
------------------------------------------------------------------------

Next, we assessed the association between anti-JCV antibody serostatus and patients' demographic and clinical features. Anti-JCV antibody-positive patients were older than antibody-negative patients (*p* = 0.001; Table [2](#Tab2){ref-type="table"}) and age was positively, but weakly, associated with anti-JCV antibody index (*r* = 0.214, *p* = 0.015; Fig. [1](#Fig1){ref-type="fig"}a). Although lymphocyte counts were similar between anti-JCV antibody-positive and antibody-negative groups, they tended to have a weak negative association with the anti-JCV antibody index (*r* = − 0.169, *p* = 0.057). Sex, disease duration, and EDSS scores did not differ by anti-JCV antibody serostatus and were not associated with the anti-JCV antibody index. Table 2Comparison of the demographic features and anti-JCV antibody status between anti-JCV antibody-positive and -negative patients with MSPositive (*n* = 86)Negative (*n* = 42)*p* valueSex, female60 (69.8%)33 (78.6%)0.399Age, years43.5 \[33.0--50.3\]35.0 \[27.8--40.3\]0.001Disease duration, years11 \[5--18\]9 \[5--15\]0.455EDSS score2.0 \[1.0--4.1\]2.0 \[1.0--3.5\]0.576Lymphocyte counts at sampling, /μL645 \[427--1402\]1158 \[521--1589\]0.139Anti-JCV antibody index2.47 \[1.15--3.29\]0.16 \[0.11--0.21\]\<  0.001Values indicate the median \[IQR\] or count (%)*EDSS* Expanded Disability Status Scale, *IQR* interquartile range, *JCV* JC virusFig. 1Correlation of anti-JCV antibody index and clinical parameters in patients with MS. **a** Correlation between anti-JCV antibody index and age in all participants (*n* = 128). **b** Correlation between anti-JCV antibody index and duration of treatment with fingolimod in MS patients under fingolimod treatment at sampling (*n* = 64). The lines represent the linear regression of the data. Translucent bands indicate 95% confidence intervals. *p* values were obtained using linear regression analyses. Ab = antibody; JCV = JC virus; mo = months; MS = multiple sclerosis

Duration of fingolimod treatment is positively associated with anti-JCV antibody index {#Sec12}
--------------------------------------------------------------------------------------

When comparing anti-JCV antibody serostatus between patients with and without a history of fingolimod treatment (*n* = 83 and 45, respectively), no significant differences were observed for the positivity rate or anti-JCV antibody index. However, patients with fingolimod treatment at sampling (*n* = 64) had a higher antibody index than those without (*n* = 64) (1.46 \[0.34--3.26\] vs 0.64 \[0.16--2.61\], *p* = 0.039; Table [3](#Tab3){ref-type="table"}). Duration of treatment with fingolimod was positively associated with the anti-JCV antibody index in patients treated with fingolimod at sampling (*r* = 0.296, *p* = 0.018; Fig. [1](#Fig1){ref-type="fig"}b), but not in patients with a history of fingolimod treatment (*r* = 0.204, *p* = 0.066). The positive correlation between duration of treatment with fingolimod and anti-JCV antibody index was still significant in patients under fingolimod treatment at sampling after correcting for age (*p* = 0.022). Table 3Comparison of the anti-JCV antibody status between MS patients with and without fingolimod treatmentHistory of fingolimod treatmentYes (*n* = 83)No (*n* = 45)*p* value  Anti-JCV antibody, positive59 (71.1%)27 (60.0%)0.239  Anti-JCV antibody index1.40 \[0.26--3.18\]0.57 \[0.16--2.97\]0.129Fingolimod treatment at samplingYes (*n* = 64)No (*n* = 64)*p* value  Anti-JCV antibody, positive47 (73.4%)39 (60.9%)0.187  Anti-JCV antibody index1.46 \[0.34--3.26\]0.64 \[0.16--2.61\]0.039Values indicate the median \[IQR\] or count (%)*IQR* interquartile range, *JCV* JC virus, *MS* multiple sclerosis

Relationship between anti-JCV serostatus and *HLA* class II alleles {#Sec13}
-------------------------------------------------------------------

When we analyzed *HLA* class II by four-digit alleles, *HLA-DRB1\*15:01* carriers (*n* = 42) had a lower anti-JCV antibody-positive rate than *DRB1\*15:01* non-carriers (50% vs 76%, *p* = 0.005; Fig. [2](#Fig2){ref-type="fig"}a). However, the positive rate of anti-JCV antibody was not different between *HLA-DRB1\*04:05* carriers (*n* = 51) and non-carriers (71% vs 65%, *p* = 0.567). When analyzing *HLA* class II by two-digit alleles, *HLA-DRB1\*15* carriers (*n* = 65) had a lower positivity rate of anti-JCV antibody compared with *DRB1\*15* non-carriers (57% vs 78%, *p* = 0.015; Fig. [2](#Fig2){ref-type="fig"}a). Again, anti-JCV antibody positive rates were similar between *HLA-DRB1\*04* carriers (*n* = 81) and non-carriers (70% vs 62%, *p* = 0.335). However, when we excluded *HLA-DRB1\*15* carriers because *DRB1\*15* had a very strong effect on anti-JCV antibody status, *DRB1\*04* carriers (*n* = 50) had a higher anti-JCV antibody positive rate compared with *DRB1\*04* non-carriers (*n* = 13) (84% vs 54%, *p* = 0.030; Fig. [2](#Fig2){ref-type="fig"}a). Anti-JCV antibody positivity rates were estimated to decrease per *HLA-DRB1\*15* allele (*p* = 0.008) and to increase per *DRB1\*04* allele when excluding *DRB1\*15* (*p* = 0.022), which suggests a gene-dosage effect (Fig. [2](#Fig2){ref-type="fig"}b). In addition, in the fingolimod-treated group, *HLA-DRB1\*15:01* carriers (*n* = 22) had a significantly lower positivity rate of anti-JCV antibody compared with *DRB1\*15:01* non-carriers (50% vs 86%, *p* = 0.006; Additional file [2](#MOESM2){ref-type="media"}: Figure S1a). Analyzing *HLA* class II by two-digits, *HLA-DRB1\*15* carriers (*n* = 32) tended to have a lower positivity rate of anti-JCV antibody compared with *DRB1\*15* non-carriers (63% vs 84%, *p* = 0.088). When *HLA-DRB1\*15* carriers were excluded, *DRB1\*04* carriers (*n* = 24) tended to have a higher anti-JCV antibody positive rate compared with *DRB1\*04* non-carriers (*n* = 8) (92% vs 63%, *p* = 0.085; Additional file [2](#MOESM2){ref-type="media"}: Figure S1a). Such associations between *HLA* alleles and anti-JCV antibody positivity rates were not seen in MS patients without fingolimod treatment (Additional file [2](#MOESM2){ref-type="media"}: Figure S1b). Fig. 2Relationship between anti-JCV antibody serostatus and *HLA* class II alleles in Japanese MS patients. **a** Anti-JCV antibody-positive rates were compared between carriers and non-carriers of each *HLA-DRB1* allele. The *HLA-DRB1* allele was analyzed and is shown as 4 digits in the left panel and as 2 digits in the right panel. *p* values were obtained using Fisher's exact test. **b** The relationships between anti-JCV antibody seropositivity rates and number of *HLA-DRB1\*15* or *DRB1\*04* alleles are shown. X in the figure indicates other alleles specified in each panel (other than *DRB1\*15* in the left panel and other than *DRB1\*04* in the middle and right panels). *p* values were obtained using the Cochran--Armitage trend test. **c** Anti-JCV antibody indices were compared between carriers and non-carriers of each *HLA-DRB1* allele. *HLA-DRB1* alleles were analyzed and are shown as 4 digits in the upper panels and as 2 digits in the lower panels. Boxes depict the median and interquartile ranges, and upper/lower whiskers extend from the hinge toward the largest/smallest values. *p* values were obtained using the Wilcoxon test. Ab = antibody; C = carriers; *HLA* = *human leukocyte antigen*; JCV = JC virus; MS = multiple sclerosis; non-C = non-carriers

The anti-JCV antibody index tended to be lower in *HLA-DRB1\*15:01* carriers compared with *DRB1\*15:01* non-carriers (median 0.35 vs 1.56, *p* = 0.083) and was lower in *DRB1\*15* carriers than in non-carriers (0.42 vs 1.97, *p* = 0.037, Fig. [2](#Fig2){ref-type="fig"}c). Moreover, in *HLA-DRB1\*15* non-carriers, *DRB1\*04* carriers tended to have a higher anti-JCV index compared with *DRB1\*04* non-carriers (2.12 vs 0.36, *p* = 0.062, Fig. [2](#Fig2){ref-type="fig"}c).

In addition to *HLA-DRB1\*04:05* and *DRB1\*15:01*, *DRB1\*04:10* carriers (*n* = 8) had a higher anti-JCV antibody index compared with non-carriers (3.29 vs 1.03, *p* = 0.021). Of *HLA-DRB1\*15:01* non-carriers, *DPB1\*04:02* carriers (*n* = 13) had a higher anti-JCV antibody index compared with non-carriers (*n* = 64) (3.20 vs 1.34, *p* = 0.008). However, anti-JCV antibody-positive rates did not differ between these allele carriers and non-carriers. No other *HLA* class II alleles were associated with anti-JCV antibody serostatus.

Age and *HLA-DRB1\*15* are independently associated with anti-JCV antibody serostatus by multivariate analyses {#Sec14}
--------------------------------------------------------------------------------------------------------------

To identify independent factors that predict anti-JCV antibody seropositivity, we performed multivariate logistic regression analysis. It showed that age was positively, and *HLA-DRB1\*15* was negatively, associated with anti-JCV antibody seropositivity (odds ratio \[OR\] = 1.06, *p* = 0.006 and OR = 0.37, *p* = 0.028, respectively; Table [4](#Tab4){ref-type="table"}). In *HLA-DRB1\*15* non-carriers (*n* = 63), *DRB1\*04* was an independent risk factor for possessing anti-JCV antibodies by multivariate logistic regression analysis (OR = 5.50, *p* = 0.023; Table [5](#Tab5){ref-type="table"}). In both analyses, fingolimod treatment itself was not an independent factor for anti-JCV antibody seropositivity. Moreover, we conducted another multivariate analysis in patients under fingolimod treatment (*n* = 64). Again, age and *HLA-DRB1\*15* were independent risk factors for anti-JCV antibody seropositivity (OR = 1.42, *p* = 0.002, and OR = 0.02, *p* = 0.022, respectively; Additional file [1](#MOESM1){ref-type="media"}: Table S2); however, treatment duration or lymphocyte count were not independent risk factors (*p* = 0.880 and 0.094, respectively; Additional file [1](#MOESM1){ref-type="media"}: Table S2). Table 4Multivariate logistic regression analysis of factors contributing to anti-JCV antibody positivity in patients with MSAll participants (*n* = 128)OR (95% CI)*p* valueAge1.06 (1.02--1.10)0.006*HLA-DRB1\*15*0.37 (0.16--0.90)0.028Sex (male)1.59 (0.63--4.00)0.321Fingolimod usage at sampling1.76 (0.52--5.89)0.361Lymphocyte count (× 1000/μL)1.14 (0.47--2.79)0.771*HLA-DRB1\*04*0.92 (0.39--2.19)0.850*CI* confidence interval, *HLA human leukocyte antigen*, *JCV* JC virus, *MS* multiple sclerosis, *OR* odds ratioTable 5Multivariate logistic regression analysis of factors contributing to anti-JCV antibody positivity in patients with MS excluding carriers of *HLA-DRB1\*15*Patients without *HLA-DRB1\*15* (*n* = 63)OR (95% CI)*p* value*HLA-DRB1\*04*5.50 (1.26--23.94)0.023Age1.04 (0.98--1.11)0.149Fingolimod usage at sampling2.40 (0.33--17.32)0.384Sex (male)1.78 (0.38--8.46)0.467Lymphocyte count (× 1000/μL)0.85 (0.20--3.66)0.832*CI* confidence interval, *HLA human leukocyte antigen*, *JCV* JC virus, *MS* multiple sclerosis, *OR* odds ratio

Discussion {#Sec15}
==========

The current study of Japanese patients with MS disclosed that *HLA-DRB1\*15* was associated with low anti-JCV antibody positivity and low antibody index, and that in the absence of *DRB1\*15*, *DRB1\*04* carriers were associated with high antibody seropositivity. Moreover, *HLA-DRB1\*15* allele and *DRB1\*04* allele without *DRB1\*15* demonstrated a gene-dosage effect on JCV antibody positivity. Additionally, ageing was positively associated with JCV antibody positivity and index while long-term fingolimod usage increased the JCV antibody index even after adjusting for age.

In addition to the strong negative association of *HLA-DRB1\*15* with JCV antibody positivity and index, we clearly showed the *HLA-DRB1\*15* allele had negative gene-dose effects and the *DRB1\*04* allele had positive gene-dose effects on anti-JCV antibody positivity. These findings indicate the influence of these gene alleles on anti-JCV antibody serostatus. This study is the first to report a lower JCV antibody index in *HLA-DRB1\*15*-positive MS patients compared with *DRB1\*15*-negative patients, which suggests that anti-JCV antibody production is decreased in *DRB1\*15* carriers. The higher frequency of JCV antibody positivity in *HLA-DRB1\*04* carriers was observed only after excluding *DRB1\*15* carriers, which suggests the dominance of *HLA-DRB1\*15* over *DRB1\*04* for anti-JCV antibody serostatus.

The findings of this study suggest that the immune control of JCV might be partly related to the strong negative association of *HLA-DRB1\*15* with JCV antibody positivity and index. However, the detailed mechanism of JCV elimination by the host remains to be elucidated. Although JCV-specific antibody titres are elevated in PML patients \[[@CR15]--[@CR17], [@CR19]\], intrathecal or serum anti-JCV antibodies do not prevent the development of PML. Most individuals who persistently shed JCV in their urine are seropositive \[[@CR6]\], some seropositive individuals are viremic \[[@CR17]\], and some individuals with PML have high copy numbers of viral DNA despite very high concentrations of anti-JCV antibodies in their cerebrospinal fluid (CSF) \[[@CR17], [@CR19]\]. Furthermore, a high JCV antibody index (\> 0.9) was strongly associated with PML in natalizumab-treated MS patients \[[@CR6]--[@CR8]\]. These observations collectively indicate that high levels of anti-JCV antibodies are not related to JCV clearance, but rather reflect the high amount of JCV and predict the risk of developing PML. Therefore, immune control of JCV is mainly dependent on cell-mediated immunity \[[@CR2]--[@CR4]\]. It was hypothesized that upon recognition of the viral capsid protein, VP-1, CD4^+^ T cells produce interferon-γ, which upregulates HLA class I molecules on JCV-infected cells. Presentation of the viral large T cell antigen by HLA class I molecules activates CD8^+^ T cells, which remove JCV-infected cells via granzyme B and other cytotoxic molecules \[[@CR19]\]. The findings that PML tends to develop in idiopathic CD4^+^ T lymphocytopenia \[[@CR34]\], that HIV-seropositive patients with PML lack CD4^+^ T cell responses to JCV \[[@CR35]\], and PML patients with low numbers of CSF CD4^+^ T cells remain persistently JCV-positive in the CSF \[[@CR36]\] collectively suggest the crucial role of CD4^+^ T cells as well as CD8^+^ cytotoxic T cells in the elimination of JCV and prevention of PML. Indeed, increased numbers of JCV-specific CD4^+^ T cells were found in the peripheral blood of PML survivors \[[@CR15], [@CR35]\]. This CD4^+^ T cell response varies according to HLA class II molecules that present the viral antigens \[[@CR20]\]. Therefore, differences in CD4^+^ T cell responses related to distinct *HLA* class II alleles are thought to influence the efficacy of JCV clearance \[[@CR13], [@CR20]\].

The negative association between *HLA-DRB1\*15* and anti-JCV antibodies suggests *HLA-DRB1\*15* carriers present JCV antigens to CD4^+^ T cells to activate CD8^+^ cytotoxic T cell responses that eliminate JCV. Eradication of JCV may result in negative or low anti-JCV antibody serostatus in *HLA-DRB1\*15* carriers. By contrast, *HLA-DRB1\*04* carriers were reported to have very low T cell responses to JCV compared with *HLA-DRB1\*15* carriers \[[@CR20]\]. Therefore, reduced T cell responses against JCV might be related to inefficient viral antigen presentation by *HLA-DRB1\*04* molecules that results in poor viral elimination and enhanced viral replication, which stimulates B cells to produce high levels of anti-JCV antibodies \[[@CR13], [@CR20], [@CR22], [@CR24]\]. The low JCV antibody levels in *HLA-DRB1\*15* carriers and high JCV antibody levels in *HLA-DRB1\*04* carriers excluding *HLA-DRB1\*15* carriers found in this study might be explained by this theory.

Although *HLA-DRB1\*15* is a common susceptibility gene for MS in Caucasians and Japanese, the phenotype frequency of *DRB1\*15:01* ranges between 45% and 60% in European MS patients (10--30% in the general population) but is only approximately 30% in Japanese patients (16--17% in the general population) \[[@CR26], [@CR27], [@CR29], [@CR37]--[@CR39]\]. Conversely, the phenotype frequency of *HLA-DRB1\*04:05* was reported to be 0.7% in MS patients in Italy \[[@CR37]\], and 0--5.3% in the European general population \[[@CR40]\], but up to 25% in the Japanese general population and around 45% in Japanese MS patients \[[@CR27], [@CR29]\]. Anti-JCV antibody seropositivity rates in MS are higher in Japanese (approximately 70% in our and previous studies) than in those of European descent (50%--60% in Europe and the USA) \[[@CR41]--[@CR43]\]. This difference might be partly explained by the difference in proportions of JCV-resistant *DRB1\*15:01* and JCV-susceptible *DRB1\*04:05* alleles between these two races. Thus, the high frequency of fingolimod-PML in Japanese may in part be related to these common susceptibility *HLA* genes. This possibility should be verified in future large-scale studies.

In fingolimod users, ageing is a risk and *DRB1\*15:01* is a strong resistance factor for anti-JCV antibody positivity. Ageing is a risk for anti-JCV antibody positivity in Europeans and Japanese \[[@CR41]--[@CR44]\]. The increase of JCV antibody index levels with the long-term usage of fingolimod, which was significant even after correcting for age, is consistent with a previous study in Japanese \[[@CR42]\]. Fingolimod acts as a functional antagonist of the sphingosine 1-phosphate receptor, which results in the inhibition of central memory T cell egress from lymph nodes \[[@CR45]\]. This effect is thought to be its beneficial mode of action in MS \[[@CR45]\]. Although the precise mechanism of fingolimod-PML is still poorly defined, T cell surveillance in the central nervous system may be dampened upon fingolimod usage. The finding that lower lymphocyte counts tended to be associated with a higher anti-JCV antibody index in our MS patients may support this mechanism. It was established that a high JCV antibody index (\> 0.9) was a risk for developing PML in natalizumab-treated MS patients \[[@CR8]\]. Although it remains to be established whether a high JCV antibody index is also a risk factor for fingolimod-PML, our study results suggest that MS patients with these risk factors, namely, aged, non-*DRB1\*15:01* carriers with anti-JCV antibody, should be frequently monitored for JCV antibody index and PML lesions by MRI upon long-term usage of fingolimod. Additionally, DMDs that lack PML risk, such as first line injectables, may be recommended for *DRB1\*04* carriers with MS because *DRB1\*04:05*-positive MS patients, especially Japanese patients, have a relatively mild disease course \[[@CR27], [@CR29]\].

There were several limitations in our study. First, a high anti-JCV antibody index is not a proven risk factor for developing PML associated with fingolimod treatment. Thus, although our study showed the differential effects of two *HLA* class II susceptible alleles for MS related to anti-JCV antibody serostatus, it does not necessarily mean that these alleles are susceptibility or resistance genes for PML development itself in MS patients treated with fingolimod. Because only four patients with fingolimod-PML have been reported in Japan, none of whom were at our institute \[[@CR11], [@CR12]\], we could not determine the *HLA* alleles in fingolimod-PML patients. Second, we did not examine JCV DNA in blood, primarily because its presence in blood is not a reliable predictor of PML. JCV DNA is often not detected in the blood of PML patients whereas it is occasionally detected in the blood of HIV-positive patients without PML \[[@CR46]\]. Furthermore, natalizumab-treated patients with detectable JCV DNA in the blood (\< 1%) did not develop PML with continued natalizumab treatment, and JCV DNA was not detectable in blood collected prior to PML development in natalizumab-treated PML patients \[[@CR47]\]. Therefore, investigating the association between anti-JCV antibody serostatus and *HLA* alleles might help us to understand the immune responses against JCV and resultant risk of PML in MS patients. Third, we did not examine T cell response to JCV peptides. Because stock sera are much easier to collect than live T cells, we investigated the correlation between anti-JCV antibodies and *HLA* alleles. Because our data suggest that differences in the immunogenetic background among races are at least partly related to anti-JCV antibody serostatus, T cell responses to JCV peptides should be examined as the next step to elucidate differences in the defense mechanism against JCV by *HLA* alleles in MS patients. Fourth, we showed data for *HLA* as four- and two-digits in this study. This was based on the hypothesis that all alleles in each allele group have a similar function. However, some alleles in the same allele group can present different antigen peptides and will therefore have different T cell activation capabilities \[[@CR20]\]. Future large-scale studies are needed to identify whether the effects on anti-JCV serostatus are similar among four-digit *HLA* alleles belonging to identical two-digit allele groups. Fifth, we did not genotype other *HLA* alleles such as *HLA-DQB1*. Because previous studies showed that the *HLA-DQB1\*06:03* haplotype was also positively associated with JCV-serostatus \[[@CR13]\] and that phenylalanine at position 9 of *HLA-DQB1* was associated with MS susceptibility in Japanese \[[@CR48]\], susceptible *HLA* alleles other than *HLA-DRB1* and *-DPB1* may also be related to the immune response against JCV in patients with MS. Therefore, future studies should assess the association between other *HLA* alleles and JCV serostatus. Finally, our study was a cross-sectional study enrolling a relatively small number of MS patients because of the rarity of MS in Japanese. The low median EDSS scores in this study cohort might reflect the milder disability of Japanese patients with MS compared with European patients with a similar disease duration and age \[[@CR49], [@CR50]\]. Therefore, we think that the relatively low EDSS scores in our patients are not necessarily related to selection bias. However, our findings should be regarded as preliminary and confirmed by large-scale longitudinal studies.

Conclusions {#Sec16}
===========

*HLA-DRB1\*15:01* and *DRB1\*15* alleles are associated with low JCV antibody positive rate and index, whereas *DRB1\*04* is associated with high JCV antibody positive rate in Japanese MS patients, excluding *DRB1\*15* carriers. Therefore, the two MS-susceptible *HLA-DRB1* alleles exert distinct effects on anti-JCV antibody serostatus in Japanese patients with MS.
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###### 

**Additional file 1: Table S1.** Phenotype frequencies of *HLA* class II alleles in study participants. **Table S2.** Multivariate logistic regression analysis of factors contributing to anti-JCV antibody positivity in patients with MS under fingolimod treatment.

###### 

**Additional file 2: Figure S1.** Relationship between anti-JCV antibody serostatus and *HLA* class II alleles in Japanese MS patients with and without fingolimod. (a, b) Anti-JCV antibody-positive rates were compared between carriers and non-carriers of each *HLA-DRB1* allele in MS patients with (a) and without (b) fingolimod treatment. The *HLA-DRB1* allele was analyzed and is shown as 4 digits in the left panel and as 2 digits in the right panel. *p* values were obtained using Fisher's exact test. Ab = antibody; C = carriers; *HLA* = *human leukocyte antigen*; JCV = JC virus; MS = multiple sclerosis; Non-C = non-carriers.

CSF

:   Cerebrospinal fluid

DMD

:   Disease-modifying drug

EDSS

:   Expanded Disability Status Scale

HLA

:   Human leukocyte antigen

IQR

:   Interquartile range

JCV

:   JC virus

MS

:   Multiple sclerosis

OR

:   Odds ratio

PML

:   Progressive multifocal leukoencephalopathy
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